ABCM Abcam plc ADRs

Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies, biochemicals, isotype controls, flow cytometry multi-color selectors, kits, loading controls, lysates, peptides, proteins, slides, tags and cell markers, and tools and reagents. Its products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics and nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells, as well as in drug discovery products and services. Abcam plc also engages in sales and distribution, and financing and investing activities, as well as sells its products online. It offers validated antibodies and other binders, and assays to the research and clinical communities to help advance the understanding of biology and causes of disease. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom. This is an ADR of a company whose stock trades outside of the U.S. as the symbol LN:ABC.

$21.08  -0.01 (-0.05%)
As of 09/22/2021 15:59:31 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  United Kingdom
Country of incorporation:  
IPO date:  10/22/2020
Outstanding shares:  226,781,415
Average volume:  55,365
Market cap:   $4,719,321,246
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    
ISIN:        
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy